XML 75 R26.htm IDEA: XBRL DOCUMENT
v3.25.4

Supplemental Financial Information | 12 Months Ended
--- | ---
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Supplemental Financial Information | Note 18. Supplemental Financial Information The following table presents the components of inventories (in thousands):
|  | December 31,
|  | 2025 |  | 2024
Raw materials |  | $ | 75,800 |  |  | $ | 71,949 |
Work-in-process |  | 12,875 |  |  | 12,322 |
Finished goods |  | 76,026 |  |  | 63,295 |
|  | $ | 164,701 |  |  | $ | 147,566 |
As of December 31, 2025 and 2024, inventories included adjustments totaling $18.0 million and $16.4 million, respectively, to record balances at lower of cost or net realizable value. The following table presents the components of property, plant, and equipment, net (in thousands):
|  | December 31, |  |  |  |
|  | 2025 |  | 2024 |  | Lives in Years
Land |  | $ | 13,631 |  |  | $ | 12,097 |  |  |  |  |
Building and building improvements (1) |  | 107,052 |  |  | 87,741 |  |  | 3 | - | 45
Equipment, furniture, and fixtures |  | 213,008 |  |  | 179,571 |  |  | 2 | - | 20
Software |  | 84,686 |  |  | 63,376 |  |  | 3 | - | 10
Other |  | 6,122 |  |  | 6,208 |  |  | 3 | - | 10
Capital investment in process |  | 60,310 |  |  | 28,020 |  |  |  |  |
Total gross property, plant, and equipment |  | 484,809 |  |  | 377,013 |  |  |  |  |
Accumulated depreciation |  | (242,206) |  |  | (206,753) |  |  |  |  |
|  | $ | 242,603 |  |  | $ | 170,260 |  |  |  |  |
(1)Building and building improvements includes right-of-use assets associated with finance leases. The following table presents the components of accrued liabilities and other (in thousands):
|  | December 31, |
|  | 2025 |  |  | 2024 |
Legal and professional costs |  | $ | 18,396 |  |  |  | $ | 17,379 |  |
Italian MedTech payback measure (1) |  | 12,839 |  |  |  | 15,981 |  |
Contract liabilities |  | 11,510 |  |  |  | 10,848 |  |
Operating lease liabilities (2) |  | 8,788 |  |  |  | 9,040 |  |
Provisions for agents, returns, and other |  | 5,322 |  |  |  | 6,744 |  |
Royalty accrual |  | 4,758 |  |  |  | 4,466 |  |
Interest payable |  | 4,638 |  |  |  | 9,479 |  |
Research and development costs |  | 1,234 |  |  |  | 6,167 |  |
Current derivative liabilities (3) |  | 99 |  |  |  | 2,915 |  |
Restructuring liability (4) |  | — |  |  |  | 2,003 |  |
Other accrued expenses |  | 26,989 |  |  |  | 33,463 |  |
|  | $ | 94,573 |  |  |  | $ | 118,485 |  |
(1)Refer to “Note 11. Commitments and Contingencies.” (2)Refer to “Note 10. Leases.” (3)Refer to “Note 7. Derivatives and Risk Management.” (4)Refer to “Note 4. Restructuring.” The following table presents the items included within foreign exchange and other income/(expense) on the consolidated statements of income (loss) (in thousands):
|  | 2025 |  | 2024 |  | 2023
Embedded derivative fair value adjustment (2025 Notes) (1) |  | $ | 2,915 |  |  | $ | 5,739 |  |  | $ | 40,106 |
Embedded derivative fair value adjustment (2029 Notes) (1) |  | (32,085) |  |  | 35,638 |  |  | — |
Capped call fair value adjustment (2025 Notes) (1) |  | (2,624) |  |  | (13,348) |  |  | (15,897) |
Capped call fair value adjustment (2029 Notes) (1) |  | 12,816 |  |  | (7,902) |  |  | — |
Interest income |  | 18,982 |  |  | 30,075 |  |  | 22,012 |
Gain on sale of asset |  | 4,128 |  |  | — |  |  | — |
Investment revaluation - Ceribell, Inc. (2) |  | (3,622) |  |  | 7,144 |  |  | — |
Impairment of investments |  | (1,112) |  |  | (5,750) |  |  | — |
FX fluctuations |  | (2,743) |  |  | (4,881) |  |  | (705) |
Other |  | 664 |  |  | 1,096 |  |  | 609 |
|  | $ | (2,681) |  |  | $ | 47,811 |  |  | $ | 46,125 |
(1)Refer to “Note 8. Fair Value Measurements.” (2)Refer to “Note 6. Investments.” The following tables present supplemental information to the consolidated statements of cash flows (in thousands):
|  | December 31,
|  | 2025 |  | 2024 |  | 2023
Cash and cash equivalents |  | $ | 635,552 |  |  | $ | 428,858 |  |  | $ | 266,504 |
Restricted cash (1) |  | — |  |  | 294,698 |  |  | 311,368 |
Cash, cash equivalents, and restricted cash |  | $ | 635,552 |  |  | $ | 723,556 |  |  | $ | 577,872 |
(1)Restricted cash represents funds held as collateral for the SNIA Litigation Guarantee. For additional information, refer to “Note 2. Basis of Presentation, Use of Accounting Estimates, and Significant Accounting Policies” and “Note 11. Commitments and Contingencies.”
|  | 2025 |  | 2024 |  | 2023
Cash paid for interest |  | $ | 31,068 |  |  | $ | 38,888 |  |  | $ | 36,910 |
Cash paid (received) for income taxes, net |  | 29,368 |  |  | 15,912 |  |  | (1,620) |
Noncash investing and financing transaction - asset obtained in exchange for finance lease obligation |  | 4,859 |  |  | — |  |  | — |

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration